Know Cancer

or
forgot password

Phase II Study of Panitumumab, Nab-paclitaxel, and Carboplatin for Patients With Primary Inflammatory Breast Cancer (IBC) Without HER2 Overexpression


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Breast Cancer

Thank you

Trial Information

Phase II Study of Panitumumab, Nab-paclitaxel, and Carboplatin for Patients With Primary Inflammatory Breast Cancer (IBC) Without HER2 Overexpression


Study Drugs:

Panitumumab is designed to prevent or slow down the growth of tumor cells by blocking the
proteins on the surface the cancer cell, called the epidermal growth factor receptor (EGFR).

Nab-paclitaxel is designed to kill tumor cells by binding a chemotherapy drug paclitaxel to
albumin, a protein made by the liver. The albumin gets into the cancer cell and releases the
paclitaxel directly to the tumor.

Carboplatin is designed to stop or slow cancer cells from growing by damaging the RNA or DNA
(the genetic material of cells) that tells the tumor cells to grow.

5-fluorouracil, epirubicin, and cyclophosphamide each work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.

Study Drug Administration:

On Day 1 of Week 1, you will receive panitumumab through a needle in your vein over 60
minutes.

After Week 1, you will receive a total of 4 cycles of PNC. Each cycle is 4 weeks.

During Cycles 1-3 (Weeks 2-13), you will receive PNC by vein once a week for 3 weeks,
followed by a week of rest. You will receive PNC through a needle in your vein. The
infusion will take 90 minutes.

During Cycle 4 (Week 14 to 17), you will receive PNC on Day 1 of Weeks 14 and 15. On Day 1
of Week 16, you will receive only carboplatin and nab-paclitaxel.

Starting on Day 1 of Week 18, you will receive FEC through a needle in your vein. The
infusion will take 90 minutes. You will receive a total of 4 cycles, each 3 weeks long,
over 12 weeks.

Surgery:

After you have completed both PNC and FEC treatments, you will have the standard of care
surgery performed. You will be given a separate consent form to read and sign.

During surgery, breast tissue samples will be collected to identify tumors as routine
procedure.

Study Visits:

Each week that you receive PNC or FEC therapy, before each dose of chemotherapy, blood
(about 1 1/2 tablespoons) will be drawn for routine tests.

Before Week 2, an optional breast core biopsy will be performed to collect tumor samples for
biomarker testing

On Week 2, every 4 weeks after that until the end of PNC, and again before FEC, the
following tests and procedures will be performed before each dose of chemotherapy.

- You will have a physical exam, including measurement of your vital signs and weight,
and breast exam.

- Blood (about 1 1/2 tablespoons) will be drawn for routine tests.

- You will be asked how well you are able to perform the normal activities of daily
living (performance status).

During Weeks 2 and 9, and before FEC therapy, the study doctor will take pictures of both of
your breasts.

Before FEC (after Cycle 4 of PNC) and again before surgery, the following tests and
procedures will be performed:

- To check the status of the disease, imaging studies including mammogram, breast MRI,
breast ultrasound, and digital photograph will be performed.

- You will have a physical exam, including vital signs, weight, and breast exam

- Blood (about 3 tablespoons) will be drawn for routine tests.

- You will be asked about any symptoms that you may have.

- The ECGs and ECHO/MUGA scans will be repeated, when the doctor thinks it is necessary.

Four (4) months after surgery, the following tests and procedures will be performed:

- You will have a physical exam, including measurement of your vital signs and weight.

- Your performance status will be recorded.

- Blood (about 1 1/2 tablespoons) will be drawn for routine tests.

- Imaging studies including chest x-ray, PET/CT, or chest and abdominal CT will be
performed to check the status of the disease.

This schedule may be changed if the study doctor thinks that it is necessary.

Length of the study:

You may remain on study treatment for up to 10 months. You will be taken off study early if
the disease gets worse or you experience intolerable side effects.

This is an investigational study. Panitumumab is FDA approved and commercially available
for the treatment of EGFR-expressing metastatic colorectal cancer with disease progression.
It's use in this study is considered to be investigational.

Nab-paclitaxel is FDA approved and commercially available for the treatment of breast cancer
after the failure of combination chemotherapy for metastatic disease or relapse within 6
months of adjuvant chemotherapy. The use of Nab-paclitaxel in this study is considered to
be investigational.

Carboplatin is FDA approved and commercially available for the treatment of IBC.

FEC is FDA approved for breast cancer in general, but not specifically for inflammatory
breast cancer.

The use of PNC and FEC together before surgery is investigational.

Up to 40 patients will take part in this study. All will be enrolled at MD Anderson.


Inclusion Criteria:



1. Histological confirmation of breast carcinoma. Pathologic evidence of dermal
lymphatic invasion should be noted but not required.

2. Clinical diagnosis of IBC (presence of inflammatory changes in the involved breast,
including diffuse erythema, heat, ridging, and peau d'orange).

3. >/= Age 18

4. ECOG performance status
5. Adequate hematologic function: Absolute neutrophil count (ANC) >/= 1.5 x 109/L,
Platelet count >/= 100 x 109/L, Hemoglobin >/= 9.0 g/dL

6. Adequate cardiac function (LVEF >/= 45%)

7. Adequate Renal function: Creatinine (Cr) (CrCl) >/= 50 mL/min calculated by the Cockroft-Gault method as follows: Male
creatinine clearance = (140 - age) x (weight in Kg) / (serum Cr x 72) Female CrCl =
(140 - age) x (weight in Kg) x 0.85 / (serum Cr x 72)

8. Adequate Hepatic function: Aspartate aminotransferase (AST) aminotransferase (ALT) bilirubin
9. Ability and willingness to sign an informed consent form for this protocol

10. If female of childbearing potential (women who are post-menopausal < 1 year, not
surgically sterilized, or not abstinent), pregnancy urine test is negative, and
agrees to be consistent and correct use of one of the following acceptable methods of
birth control: male partner who is sterile prior to the female subject entry into the
study and is the sole sexual partner for that female subject; any intrauterine device
(IUD) with a documented failure rate of less than 1% per year; oral contraception, or
barrier methods, including diaphragm or condom with a spermicide.

Exclusion Criteria:

1. History of radiation or chemotherapy

2. HER2-positive breast carcinoma (IHC staining more than 3+ or HER2 gene amplification
by FISH)

3. History or current diagnosis of metastatic or recurrent breast cancer

4. History of other malignancies (except for cured non-melanomatous skin cancer or cured
cervical carcinoma in situ, or malignancies with no evidence of disease and no
treatment for >5 years)

5. Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus,
acute or chronic active hepatitis B infection

6. History of extensive interstitial lung disease e.g. pneumonitis or pulmonary fibrosis
or any evidence of extensive interstitial lung disease on baseline chest CT scan

7. Patient with other significant medical or psychiatric condition that would make
assessment of toxicity or efficacy difficult.

8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

9. Peripheral neuropathy >= Gr II

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Pathologic Complete Response (CR) Rate

Outcome Time Frame:

Assessed after 14 weeks (following PNC and FEC preoperative chemotherapy treatment).

Safety Issue:

No

Principal Investigator

Naoto Ueno, MD, PHD

Investigator Role:

Study Chair

Investigator Affiliation:

UT MD Anderson Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

2008-0372

NCT ID:

NCT01036087

Start Date:

November 2010

Completion Date:

Related Keywords:

  • Breast Cancer
  • Inflammatory Breast Cancer
  • IBC
  • Primary breast carcinoma
  • HER2 negative overexpression
  • Panitumumab
  • Vectibix
  • Nab-paclitaxel
  • Paclitaxel
  • Abraxane
  • Carboplatin
  • Paraplatin
  • PNC
  • 5-fluorouracil
  • 5-FU
  • Adrucil
  • Efudex
  • Epirubicin
  • Ellence
  • Cyclophosphamide
  • Cytoxan
  • Neosar
  • FEC
  • Breast Neoplasms
  • Inflammatory Breast Neoplasms

Name

Location

UT MD Anderson Cancer CenterHouston, Texas  77030